Xiao‐Feng Le

Also affiliated with The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations”.

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

ESMO Open(2025)10.1016/j.esmoop.2025.104136

N/A

0.241DataRank · unranked

4 citations

Chieh Tseng, Hai T. Tran, Aung Naing, Ecaterina E. Dumbrava, DD Karp +9 more

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

Annals of Oncology(2025)10.1016/j.annonc.2025.09.140

N/A

0DataRank · unranked

8 citations

Y. Xia, Ke Pan, Fangdi Sun, Aaron C. Tan, Xinran Dong +31 more